Literature DB >> 15712223

Seventeen novel PLP1 mutations in patients with Pelizaeus-Merzbacher disease.

Christian A Hübner1, Ulrike Orth, Arne Senning, Cordula Steglich, Alfried Kohlschütter, Rudolf Korinthenberg, Andreas Gal.   

Abstract

Pelizaeus-Merzbacher disease (PMD) is a rare X-chromosomal neurodegenerative disorder that affects primarily the white matter of the central nervous system and is caused by mutations of the PLP1 (proteolipid protein 1) gene. We performed mutation analysis of 133 male patients with suspected PMD. Following SSCP analysis of all coding exons of PLP1, we found most likely pathogenic mutations (single base substitutions and small rearrangements) including 17 novel sequence variants in 21 (15.8%) patients. Most patients with missense mutations had a severe phenotype. Twelve patients (9.0%) carried a duplication of the entire gene, as demonstrated by quantitative real-time PCR, and presented with a variable clinical phenotype including mild, classical, and severe courses of disease. Two patients had large deletions, spanning approximately 115 kb, that included the PLP1 gene. In total, we identified pathogenic mutations involving PLP1 in 35 (26.3%) of the 133 patients analyzed. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712223     DOI: 10.1002/humu.9314

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Prioritizing genes for X-linked diseases using population exome data.

Authors:  Xiaoyan Ge; Pui-Yan Kwok; Joseph T C Shieh
Journal:  Hum Mol Genet       Date:  2014-09-12       Impact factor: 6.150

2.  Differences in endoplasmic-reticulum quality control determine the cellular response to disease-associated mutants of proteolipid protein.

Authors:  Peristera Roboti; Eileithyia Swanton; Stephen High
Journal:  J Cell Sci       Date:  2009-10-13       Impact factor: 5.285

3.  PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing.

Authors:  Jennifer R Taube; Karen Sperle; Linda Banser; Pavel Seeman; Barbra Charina V Cavan; James Y Garbern; Grace M Hobson
Journal:  Hum Mol Genet       Date:  2014-06-01       Impact factor: 6.150

Review 4.  Neurogenetics of Pelizaeus-Merzbacher disease.

Authors:  M Joana Osório; Steven A Goldman
Journal:  Handb Clin Neurol       Date:  2018

5.  Altered PLP1 splicing causes hypomyelination of early myelinating structures.

Authors:  Sietske H Kevelam; Jennifer R Taube; Rosalina M L van Spaendonk; Enrico Bertini; Karen Sperle; Mark Tarnopolsky; Davide Tonduti; Enza Maria Valente; Lorena Travaglini; Erik A Sistermans; Geneviève Bernard; Coriene E Catsman-Berrevoets; Clara D M van Karnebeek; John R Østergaard; Richard L Friederich; Mahmoud Fawzi Elsaid; Jolanda H Schieving; Maja Tarailo-Graovac; Simona Orcesi; Marjan E Steenweg; Carola G M van Berkel; Quinten Waisfisz; Truus E M Abbink; Marjo S van der Knaap; Grace M Hobson; Nicole I Wolf
Journal:  Ann Clin Transl Neurol       Date:  2015-05-01       Impact factor: 4.511

6.  Morpholino Antisense Oligomers as a Potential Therapeutic Option for the Correction of Alternative Splicing in PMD, SPG2, and HEMS.

Authors:  Stephanie Tantzer; Karen Sperle; Kaitlin Kenaley; Jennifer Taube; Grace M Hobson
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-05       Impact factor: 8.886

7.  Genotype-phenotype correlation and natural history analyses in a Chinese cohort with pelizaeus-merzbacher disease.

Authors:  Ruoyu Duan; Haoran Ji; Huifang Yan; Junyu Wang; Yu Zhang; Qian Zhang; Dongxiao Li; Binbin Cao; Qiang Gu; Ye Wu; Yuwu Jiang; Ming Li; Jingmin Wang
Journal:  Orphanet J Rare Dis       Date:  2022-03-28       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.